Skip to main content

 Scientific publications

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Authors : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77

Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach.

Authors : Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Larsimont D, Park M, Rothé F, Stagg J, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Authors : Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 25

MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries.

Authors : Alexandri C, Stamatopoulos B, Rothé F, Bareche Y, Devos M, Demeestere I
Year : 2019
Journal : Sci Rep
Volume : 9
Pages : 9636

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Authors : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Authors : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

ESR1 mutations in metastatic lobular breast cancer patients.

Authors : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 9

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Authors : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, Sotiriou C, Jamieson SMF
Year : 2019
Journal : Br J Cancer

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Authors : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 895-902

Genomic hotspots but few recurrent fusion genes in breast cancer.

Authors : Fimereli D, Fumagalli D, Brown D, Gacquer D, Rothé F, Salgado R, Larsimont D, Sotiriou C, Detours V
Year : 2018
Journal : Genes Chromosomes Cancer
Volume : 57(7)
Pages : 331-338

Immune Infiltration in Invasive Lobular Breast Cancer.

Authors : Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(7)
Pages : 768-776

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Authors : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pages : 560-567

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.

Authors : Jose V, Fumagalli D, Rothé F, Majjaj S, Loi S, Michiels S, Sotiriou C
Year : 2018
Journal : PLoS ONE
Volume : 13
Pages : e0203346

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Authors : Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : NPJ Breast Cancer
Volume : 4
Pages : 23

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Authors : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Year : 2018
Journal : Ann Oncol
Volume : 29(8)
Pages : 1777-1783

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Authors : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Year : 2017
Journal : Nat Commun
Volume : 8
Pages : 14944

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Authors : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Year : 2017
Journal : JAMA Oncol
Volume : 3
Pages : 227-234

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Authors : Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart-Gebhart M, Ignatiadis M, Sotiriou C, Roger PP
Year : 2017
Journal : EMBO Mol Med
Volume : 9
Pages : 1052-1066

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Authors : Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart-Gebhart M, Loi S, Sotiriou C
Year : 2017
Journal : NPJ Breast Cancer
Volume : 3
Pages : 23

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Authors : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Year : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212